The traditional Chinese medical compound Rocaglamide protects nonmalignant primary cells from DNA damage-induced toxicity by inhibition of p53 expression

Cell Death and Disease

Volumn 5, Issue 1, 2014, Pages

  Becker, M S ^a   Schmezer, P ^a   Breuer, R ^a   Haas, S F ^a   Essers, M A ^a   Krammer, P H ^a   Li Weber, M ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Anticancer drug; Apoptosis; Chemoprotection; p53; Rocaglamide; TCM

Indexed keywords

ADJUVANT; ANTINEOPLASTIC AGENT; ATROPINE; BAICALEIN; BAICALIN; BLEOMYCIN; BORTEZOMIB; CAFFEINE; COUMARIN; CURCUMIN; DOXORUBICIN; EMODIN; ETOPOSIDE; PLANT MEDICINAL PRODUCT; PROTEIN P53; QUERCETIN; RESVERATROL; ROCAGLAMIDE; TENIPOSIDE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER CELL; CELL PROTECTION; CHINESE MEDICINE; DNA DAMAGE; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIMARY CELL CULTURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; SPLEEN CELL; TRADITIONAL MEDICINE; UPREGULATION; WILD TYPE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZOFURANS; CELL LINE, TUMOR; DNA DAMAGE; DOWN-REGULATION; DRUG INTERACTIONS; DRUGS, CHINESE HERBAL; HUMANS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASMS; PROTECTIVE AGENTS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84891780689     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2013.528     Document Type: Article

References (60)

1. Roos WP, Kaina B. DNA damage-induced cell death: from specific DNA lesions to the DNA damage response and apoptosis. Cancer Lett 2013; 332: 237-248.
2. Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 2004; 100: 228-237.
3. Sinkule JA. Etoposide: a semisynthetic epipodophyllotoxin. Chemistry, pharmacology, pharmacokinetics, adverse effects and use as an antineoplastic agent. Pharmacotherapy 1984; 4: 61-73.
4. Mackall C, Fleisher T, Brown M, Magrath I, Shad A, Horowitz M et al. Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood 1994; 84: 2221-2228.
5. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966; 64: 328-340.
6. Bonner WM, Redon CE, Dickey JS, Nakamura AJ, Sedelnikova OA, Solier S et al. GammaH2AX and cancer. Nat Rev Cancer. 2008; 8: 957-967.
7. Goel HC, Prasad J, Singh S, Sagar RK, Agrawala PK, Bala M et al. Radioprotective potential of an herbal extract of Tinospora cordifolia. J Radiat Res 2004; 45: 61-68.
8. Mehendale SR, Aung HH, Yin J-J, Lin E, Fishbein A, Wang C-Z et al. Effects of antioxidant herbs on chemotherapy-induced nausea and vomiting in a rat-pica model. Am J Chin Med 2004; 32: 897-905.
9. Lee SE, Oh H, Yang JA, Jo SK, Byun MW, Yee ST et al. Radioprotective effects of two traditional Chinese medicine prescriptions: si-wu-tang and si-jun-zi-tang. Am J Chin Med 1999; 27: 387-396.
10. Lam W, Bussom S, Guan F, Jiang Z, Zhang W, Gullen EA et al. The four-herb Chinese medicine PHY906 reduces chemotherapy-induced gastrointestinal toxicity. Sci Transl Med 2010; 2: 45ra59.
11. Farrell MP, Kummar S. Phase I/IIA randomized study of PHY906, a novel herbal agent, as a modulator of chemotherapy in patients with advanced colorectal cancer. Clin Colorectal Cancer 2003; 2: 253-256.
12. Chan KKL, Yao TJ, Jones B, Zhao JF, Ma FK, Leung CY et al. The use of Chinese herbal medicine to improve quality of life in women undergoing chemotherapy for ovarian cancer: a double-blind placebo-controlled randomized trial with immunological monitoring. Ann Oncol 2011; 22: 2241-2249.
13. Lu King M, Chiang C-C, Ling H-C, Fujita E, Ochiai M, McPhail AT. X-Ray crystal structure of rocaglamide, a novel antileulemic 1H-cyclopenta[b] benzofuran from Aglaia elliptifolia. J Chem Soc Chem Commun 1982; 20: 1150-1151.
14. Kim S, Salim AA, Swanson SM, Kinghorn AD. Potential of cyclopenta[b]benzofurans from Aglaia species in cancer chemotherapy. Anticancer Agents Med Chem 2006; 6: 319-345.
15. Ebada SS, Lajkiewicz N, Porco JA, Li-Weber M, Proksch P. Chemistry and biology of rocaglamides (= flavaglines) and related derivatives from aglaia species (meliaceae). Prog Chem Org Nat Prod 2011; 94: 1-58.
16. Ohse T, Ohba S, Yamamoto T, Koyano T, Umezawa K. Cyclopentabenzofuran lignan protein synthesis inhibitors from Aglaia odorata. J Nat Prod 1996; 59: 650-652.
17. Lee SK, Cui B, Mehta RR, Kinghorn AD, Pezzuto JM. Cytostatic mechanism and antitumor potential of novel 1H-cyclopenta[b]benzofuran lignans isolated from Aglaia elliptica. Chem Biol Interact 1998; 115: 215-228.
18. Polier G, Neumann J, Thuaud F, Ribeiro N, Gelhaus C, Schmidt H et al. The natural anticancer compounds rocaglamides inhibit the Raf-MEK-ERK pathway by targeting prohibitin 1 and 2. Chem Biol 2012; 19: 1093-1104.
19. Sadlish H, Galicia-Vazquez G, Paris CG, Aust T, Bhullar B, Chang L et al. Evidence for a functionally relevant rocaglamide binding site on the eIF4A-RNA complex. ACS Chem Biol 2013; 8: 1519-1527.
20. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2002; 2: 594-604.
21. Roos WP, Kaina B. DNA damage-induced cell death by apoptosis. Trends Mol Med 2006; 12: 440-450.
22. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 1998; 273: 5858-5868.
23. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74: 957-967.
24. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303: 844-848.
25. Egle A, Harris AW, Bouillet P, Cory S. Bim is a suppressor of Myc-induced mouse B cell leukemia. Proc Natl Acad Sci USA 2004; 101: 6164-6169.
26. Feuerborn A, Möritz C, Von Bonin F, Dobbelstein M, Trümper L, Stürzenhofecker B et al. Dysfunctional p53 deletion mutants in cell lines derived from Hodgkin's lymphoma. Leuk Lymphoma 2006; 47: 1932-1940.
27. Cheng J, Haas M. Frequent mutations in the p53 tumor suppressor gene in human leukemia T-cell lines. Mol Cell Biol 1990; 10: 5502-5509.
28. Zhu JY, Giaisi M, Köhler R, Müller WW, Mühleisen A, Proksch P et al. Rocaglamide sensitizes leukemic T cells to activation-induced cell death by differential regulation of CD95L and c-FLIP expression. Cell Death Differ 2009; 16: 1289-1299.
29. Forbes S, Clements J, Dawson E, Bamford S, Webb T, Dogan A et al. Cosmic 2005. Br J Cancer 2006; 94: 318-322.
30. Zhou M, Gu L, Yeager AM, Findley HW. Sensitivity to Fas-mediated apoptosis in pediatric acute lymphoblastic leukemia is associated with a mutant p53 phenotype and absence of Bcl-2 expression. Leukemia 1998; 12: 1756-1763.
31. Jia LQ, Osada M, Ishioka C, Gamo M, Ikawa S, Suzuki T et al. Screening the p53 status of human cell lines using a yeast functional assay. Mol Carcinog 1997; 19: 243-253.
32. Barbarotto E, Corallini F, Rimondi E, Fadda R, Mischiati C, Grill V et al. Differential effects of chemotherapeutic drugs versus the MDM-2 antagonist nutlin-3 on cell cycle progression and induction of apoptosis in SKW6.4 lymphoblastoid B-cells. J Cell Biochem 2008; 104: 595-605.
33. Fujita T, Kiyama M, Tomizawa Y, Kohno T, Yokota J. Comprehensive analysis of p53 gene mutation characteristics in lung carcinoma with special reference to histological subtypes. Int J Oncol 1999; 15: 927-934.
34. Marine J-C, Lozano G. Mdm2-mediated ubiquitylation: p53 and beyond. Cell Death Differ 2010; 17: 93-102.
35. Lee JT, Gu W. The multiple levels of regulation by p53 ubiquitination. Cell Death Differ 2010; 17: 86-92.
36. Takagi M, Absalon MJ, McLure KG, Kastan MB. Regulation of p53 translation and induction after DNA damage by ribosomal protein L26 and nucleolin. Cell 2005; 123: 49-63.
37. Gajjar M, Candeias MM, Malbert-Colas L, Mazars A, Fujita J, Olivares-Illana V et al. The p53 mRNA-Mdm2 interaction controls Mdm2 nuclear trafficking and is required for p53 activation following DNA damage. Cancer Cell 2012; 21: 25-35.
38. Bleumink M, Köhler R, Giaisi M, Proksch P, Krammer PH, Li-Weber M. Rocaglamide breaks TRAIL resistance in HTLV-1-associated adult T-cell leukemia/lymphoma by translational suppression of c-FLIP expression. Cell Death Differ 2011; 18: 362-370.
39. Cencic R, Carrier M, Galicia-Vázquez G, Bordeleau M-E, Sukarieh R, Bourdeau A et al. Antitumor activity and mechanism of action of the cyclopenta[b]benzofuran, silvestrol. PLoS One 2009; 4: e5223.
40. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. p53 is required for radiationinduced apoptosis in mouse thymocytes. Nature 1993; 362: 847-849.
41. Westphal CH, Hoyes KP, Canman CE, Christine E, Leder P, Huang X et al. Loss of atm Radiosensitizes Multiple p53 Null Tissues. Cancer Res 1998; 58: 5637-5639.
42. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408: 307-310.
43. Martinez-Rivera M, Siddik ZH. Resistance and gain-of-resistance phenotypes in cancers harboring wild-type p53. Biochem Pharmacol 2012; 83: 1049-1062.
44. Zhu JY, Lavrik IN, Mahlknecht U, Giaisi M, Proksch P, Krammer PH et al. The traditional Chinese herbal compound rocaglamide preferentially induces apoptosis in leukemia cells by modulation of mitogen-activated protein kinase activities. Int J Cancer 2007; 121: 1839-1846.
45. Balmanno K, Cook SJ. Tumour cell survival signalling by the ERK1/2 pathway. Cell Death Differ 2009; 16: 368-377.
46. Wang X, Jiang X. Mdm2 and MdmX partner to regulate p53. FEBS Lett 2012; 586: 1390-1396.
47. Christophorou MA, Ringshausen I, Finch AJ, Swigart LB, Evan GI. The pathological response to DNA damage does not contribute to p53-mediated tumour suppression. Nature 2006; 443: 214-217.
48. Hinkal G, Parikh N, Donehower LA. Timed somatic deletion of p53 in mice reveals age-associated differences in tumor progression. PLoS One 2009; 4: e6654.
49. Komarov PGA. Chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 1999; 285: 1733-1737.
50. Li T, Kon N, Jiang L, Tan M, Ludwig T, Zhao Y et al. Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell 2012; 149: 1269-1283.
51. Brady CA, Jiang D, Mello SS, Johnson TM, Jarvis LA, Kozak MM et al. Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression. Cell 2011; 145: 571-583.
52. Bernard Y, Ribeiro N, Thuaud F, Türkeri G, Dirr R, Boulberdaa M et al. Flavaglines alleviate doxorubicin cardiotoxicity: implication of Hsp27. PLoS One 2011; 6: e25302.
53. Ribeiro N, Thuaud F, Bernard Y, Gaiddon C, Cresteil T, Hild A et al. Flavaglines as potent anticancer and cytoprotective agents. J Med Chem 2012; 55: 10064-10073.
54. Jacobs WB, Kaplan DR, Miller FD. The p53 family in nervous system development and disease. J Neurochem 2006; 97: 1571-1584.
55. Trimmer PA, Smith TS, Jung AB, Bennett JP. Dopamine neurons from transgenic mice with a knockout of the p53 gene resist MPTP neurotoxicity. Neurodegeneration 1996; 5: 233-239.
56. Fahrig T, Gerlach I, Horva E. A synthetic derivative of the natural product Rocaglaol is a potent inhibitor of cytokine-mediated signaling and shows neuroprotective activity in vitro and in animal models of Parkinson's Disease and traumatic brain injury. Mol Pharmacol 2005; 67: 1544-1555.
57. Klas C, Debatin KM, Jonker RR, Krammer PH. Activation interferes with the APO-1 pathway in mature human T cells. Int Immunol 1993; 5: 625-630.
58. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991; 139: 271-279.
59. Greve B, Bölling T, Amler S, Rössler U, Gomolka M, Mayer C et al. Evaluation of different biomarkers to predict individual radiosensitivity in an inter-laboratory comparison-lessons for future studies. PLoS One 2012; 7: e47185.
60. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001; 29: e45.